2026年1月,尽管有强劲的收入和增长前景,但PTC治疗局内部人员出售了数十万库存。 PTC Therapeutics insiders sold hundreds of thousands in stock in Jan 2026 despite strong earnings and growth outlook.

2026年1月6日至12日, 包括执行副总裁李史考特(Lee Scott Golden)和Eric Pauwels(Eric Pauwers)在内的多位PTC治疗内幕人士出售了数十万美元的股份, On January 6–12, 2026, multiple PTC Therapeutics insiders, including Executive Vice President Lee Scott Golden and Eric Pauwels, sold shares totaling hundreds of thousands of dollars, reducing their stakes amid strong company performance. 据该公司报告,2025年Q4产品收入为9 250万美元,2025年全年收入为8.23亿美元,超过指导水平,预计2026年产品收入将增长19%至36%。 The firm reported Q4 2025 revenue of $92.5 million for its Sephience product and full-year 2025 revenue of $823 million, exceeding guidance, with 2026 product revenue expected to grow 19% to 36%. PTC持有19.4亿美元的现金,市场上限为62.3亿美元。 PTC holds $1.94 billion in cash and has a market cap of $6.23 billion. 尽管金融表现良好,分析师评为“坚持”评级,但内幕销售引起了投资者的关切,尽管这可能反映了个人财务规划。 Despite positive financials and a “Hold” analyst rating, insider sales have raised investor concerns, though they may reflect personal financial planning. 1月12日,该库存以77.59美元关闭。 The stock closed at $77.59 on January 12.